{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:18Z","timestamp":1793064198986,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain incompletely characterized. We included patients with RRMM treated with ide-cel between May 2021 and April 2023 across 11 US academic institutions. Visceral or soft tissue lesions non-contiguous from bone was classified as EMD. Time-to-event analyses were performed from date of ide-cel infusion. Among 351 patients, 84 (24%) had EMD prior to infusion. The median follow-up from ide-cel infusion was 18.2 months (95% CI: 17-19.3). The day 90 overall response rates (ORR) were 52% vs. 82% for the EMD and non-EMD cohorts, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The median progression-free survival (PFS) was 5.3 months (95% CI: 4.1\u20136.9) for the EMD cohort vs. 11.1 months (95% CI: 9.2\u201312.6;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) for the non-EMD cohort. In a multivariable analysis, EMD was an independent predictor of inferior PFS [hazard ratio 1.5 (1.1\u20132.2),\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02]. The median overall survival was 14.8 months [95% CI: 9-Not reached (NR)] vs. 26.9 months (26.3 vs. NR,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) for the EMD and non-EMD cohorts, respectively. Extramedullary disease represents an independent predictor of inferior day 90 ORR and PFS among patients treated with ide-cel.\n                  <\/jats:p>","DOI":"10.1186\/s13045-024-01555-4","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:01:35Z","timestamp":1717675295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel"],"prefix":"10.1186","volume":"17","author":[{"given":"Saurabh","family":"Zanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Castaneda","family":"Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry D.","family":"Anderson Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"issue":"9","key":"1555_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321.","journal-title":"Leukemia"},{"issue":"3","key":"1555_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138.","journal-title":"Leukemia"},{"issue":"3","key":"1555_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"2022\/03\/21","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;2022\/03\/21(3):45.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1555_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761\u20137.","journal-title":"Haematologica"},{"issue":"3","key":"1555_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194(3):496\u2013507.","journal-title":"Br J Haematol"},{"issue":"4","key":"1555_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"1555_CR7","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","volume":"41","author":"YC Cohen","year":"2023","unstructured":"Cohen YC, Morillo D, Gatt ME, Sebag M, Kim K, Min C-K, et al. First results from the RedirecTT-1 study with teclistamab (tec)\u2009+\u2009talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16suppl):8002\u20138002.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98(10):1540\u20139.","journal-title":"Am J Hematol"},{"key":"1555_CR9","doi-asserted-by":"crossref","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leuk 2020 2020\/01\/01; 34(1): 1\u201320.","DOI":"10.1038\/s41375-019-0660-0"},{"issue":"5","key":"1555_CR10","first-page":"890","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890\u20137.","journal-title":"Haematologica"},{"issue":"1","key":"1555_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosi\u00f1ol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105(1):201\u20138.","journal-title":"Haematologica"},{"issue":"9","key":"1555_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-022-00730-5","volume":"2022\/09\/16","author":"R Jim\u00e9nez-Segura","year":"2022","unstructured":"Jim\u00e9nez-Segura R, Rosi\u00f1ol L, Cibeira MT, Fern\u00e1ndez de Larrea C, Tovar N, Rodr\u00edguez-Lobato LG, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022;2022\/09\/16(9):135.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1555_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"1555_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"key":"1555_CR15","doi-asserted-by":"crossref","unstructured":"Pan D, Mouhieddine TH, Fu W, Moshier E, Parekh S, Jagannath S et al. Outcomes after CAR T cells in multiple myeloma patients with Extramedullary and Paramedullary Disease. Blood 2023 2023\/11\/02\/; 142: 1006.","DOI":"10.1182\/blood-2023-177749"},{"key":"1555_CR16","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of Outcome after B-Cell Maturation Antigen-Directed chimeric Antigen receptor T-Cell therapy in Relapsed\/Refractory multiple myeloma. J Clin Oncol. 2024 Feb;15:Jco2302232."},{"issue":"8","key":"1555_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1555_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18F-FDG\u2013PET\/CT according to Deauville Criteria for Metabolic Complete Response Definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(2):116\u201325.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1555_CR19","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a Report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1555_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and neurologic toxicity Associated with Immune Effector cells. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation. 2019;25(4):625\u201338.","journal-title":"Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"1555_CR21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. U.S. Department of Health and Human Services. 2017 Nov. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 28 Jan 2022."},{"issue":"11","key":"1555_CR22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","volume":"97","author":"J Blad\u00e9","year":"2012","unstructured":"Blad\u00e9 J, de Larrea CF, Rosi\u00f1ol L. Extramedullary involvement in multiple myeloma. Haematologica. 2012;97(11):1618\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"1555_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288\u201391.","journal-title":"Leukemia"},{"issue":"6","key":"1555_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"key":"1555_CR25","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 2023 2023\/09\/01; 29(9): 2259\u201367.","DOI":"10.1038\/s41591-023-02528-9"},{"issue":"24","key":"1555_CR26","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"key":"1555_CR27","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 2021 2021\/07\/24\/; 398(10297): 314\u201324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"issue":"3","key":"1555_CR28","doi-asserted-by":"publisher","first-page":"e283281","DOI":"10.1016\/j.jtct.2023.12.010","volume":"30","author":"OS Akhtar","year":"2024","unstructured":"Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, et al. Simple score of albumin and CRP predicts high-Grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transpl Cell Ther. 2024;30(3):e283281\u2013283210.","journal-title":"Transpl Cell Ther"},{"key":"1555_CR29","doi-asserted-by":"crossref","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H et al. Safety and Efficacy of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: A Real-World Experience. Transplantation and Cellular Therapy 2024 2024\/03\/01\/; 30(3): 308.e301-308.e313.","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"1555_CR30","doi-asserted-by":"crossref","unstructured":"Sidana S, Ahmed N, Akhtar OS, Heim M, Brazauskas R, Hansen DK et al. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma. Blood 2023 2023\/11\/02\/; 142: 1027.","DOI":"10.1182\/blood-2023-181762"},{"key":"1555_CR31","doi-asserted-by":"crossref","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 2024 2024\/01\/20.","DOI":"10.1038\/s41375-024-02154-5"},{"issue":"1","key":"1555_CR32","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","volume":"2022\/06\/29","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu Y-M, Mishler J, Hall S, Mannan R, Wang L, et al. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;2022\/06\/29(1):3750.","journal-title":"Nat Commun"},{"key":"1555_CR33","doi-asserted-by":"crossref","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia 2024 2024\/03\/16.","DOI":"10.1038\/s41375-024-02206-w"},{"issue":"1","key":"1555_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12885-020-06870-w","volume":"20","author":"MV Firsova","year":"2020","unstructured":"Firsova MV, Mendeleeva LP, Kovrigina AM, Solovev MV, Savchenko VG. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. BMC Cancer. 2020;20(1):346.","journal-title":"BMC Cancer"},{"key":"1555_CR35","doi-asserted-by":"crossref","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 2017 2017\/10\/01; 31(10): 2181\u201390.","DOI":"10.1038\/leu.2017.41"},{"key":"1555_CR36","doi-asserted-by":"crossref","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Reviews Clin Oncol 2023 2023\/06\/01; 20(6): 359\u201371.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"1555_CR37","doi-asserted-by":"crossref","unstructured":"Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS et al. Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. J Clin Invest 2023; 133(15).","DOI":"10.1172\/JCI167629"},{"issue":"5","key":"1555_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","volume":"105","author":"AJ Sim","year":"2019","unstructured":"Sim AJ, Jain MD, Figura NB, Chavez JC, Shah BD, Khimani F, et al. Radiation Therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma. Int J Radiat Oncol Biol Phys. 2019;105(5):1012\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1555_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ajh.27155","volume":"99","author":"O Saifi","year":"2024","unstructured":"Saifi O, Lester SC, Breen WG, Rule WG, Lin Y, Bennani NN, et al. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed\/refractory non-hodgkin lymphoma: a multicenter consensus approach. Am J Hematol. 2024;99(1):124\u201334.","journal-title":"Am J Hematol"},{"issue":"23","key":"1555_CR40","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath SH, Cohen AD, Lacey SF, Davis MM, Garfall AL, Melenhorst JJ, et al. The safety of bridging Radiation with Anti-BCMA CAR T-Cell therapy for multiple myeloma. Clin Cancer Res. 2021;27(23):6580\u201390.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1555_CR41","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","volume":"7","author":"EL Smith","year":"2019","unstructured":"Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, et al. BCMA-Targeted CAR T-cell therapy plus Radiotherapy for the treatment of Refractory Myeloma reveals potential synergy. Cancer Immunol Res. 2019;7(7):1047\u201353.","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"1555_CR42","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399.","journal-title":"Blood Adv"},{"issue":"6","key":"1555_CR43","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1555_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ejh.14074","volume":"112","author":"M Ho","year":"2024","unstructured":"Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities. Eur J Haematol. 2024;112(2):197\u2013210.","journal-title":"Eur J Haematol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01555-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:02:59Z","timestamp":1717675379000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01555-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01555-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.Z., O.P, R.G., D.D. G.K, M.H, P.F, C.W.A.L-C.: no relevant disclosures. S.S.: Consulting or advisory role for Janssen, Bristol-Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, Abbvie and Regeneron; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis and Bristol-Myers Squibb; L.S.: Consulting or Advisory role for Janssen Oncology; O.C.P.: Consulting or Advisory role for BMS\/Celgene\/Juno, Legend Biotech; A.A.: Consulting or Advisory role for BMS, Karyopharm, Research funding from Abbvie, Adaptive biotechnologies; J.A.D.: consultancy for Janssen; H.H.; Consulting or Advisory role for Sanofi, BMS\/Celgene, Janssen; speaker\u2019s bureau: Janssen, Karyopharm, Amgen; D.S.: Consulting or Advisory role for Sanofi, GSK, BMS\/Celgene, Janssen, Abbvie, Pfizer, Arcellx, BiolineRx, Astrazeneca, research funding from Pfizer; L.D.A. Jr: consulting or advisory board role for Janssen, Celgene, Bristol Myers Squibb, Amgen, GlaxoSmithKline, AbbVie, BeiGene, Cellectar, Sanofi, Karyopharm, Oncopeptides, and Prothena. J.M: Honoraria: Kite, a Gilead company, AlloVir, Magenta Therapeutics, Nektar, Sana Biotechnology; Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, AlloVir, Magenta Therapeutics, EcoR1 Capital, CRISPR therapeutics; Speakers\u2019 Bureau: Kite\/Gilead; Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst); Travel, Accommodations, Expenses: Kite, a Gilead company; A.R.: consultant for Sanofi, BMS, Janssen, and Adaptive. C.R. is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva; C.L.F: horonoraria and consulting- Bristol Myers Squibb, Seattle Genetics, Celgene, AbbVie, Sanofi, Incyte, Amgen, ONK Therapeutics & Janssen; and research funding from Bristol Myers Squibb, Janssen, and Roche\/Genentech; F.L.L.: Scientific Advisory Role\/Consulting Fees: A2, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Umoja, Pfizer; Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), 2SeventyBio (Institutional), BMS (Institutional), National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer S.R.: Honoraria: BMs, Jansssen; Consulting or Advisory Role: Genentech; Research Funding: Janssen, C4 therapeutics, Gracell, Heidelberg Pharma; J.K.: Consulting or Advisory Role: Janssen Oncology; Honoraria: GPCR therapeutics; Y.L.: Consulting or Advisory role: Kite\/Gilead, BMS, Vineti, Janssen Oncology, Pfizer; Sanofi, NexImmune, Caribou biosciences, Regeneron, Genentech, Fosun Kite, Chimeric Therapeutics, Adicet Bio, Nektar; Research Funding: Janssen Oncoloyg, BMS, Merck, Takeda, Boston Scientific, Kite\/Gilead, Bluebird Bio; K.K.P.: Consulting or Advisory Role: Celgene, BMS, Janssen, Pfizer, Arcellx, Karyopharm Therapeutics, Merck, Cellectis, Caribou Biosciences, Takeda, Abbvie, Travel, Accomodation, Expenses: BMS; Research funding: Celgene\/BMs, Takeda, Janssen, Cellectis, Nektar, Abbvie\/Genentech, Precision Biosciences, Allogene Therapeutics; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech\/Rocher, Abbvie, BMS\/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS\/Celgene; D.K.H.: Research funding from Bristol-Myers Squibb, Karyopharm, and Adaptive Biotech; Consulting or advisory role for Bristol-Myers Squibb, Janssen, Pfizer, and Karyopharm. D.K.H is also supported by the Pentecost Family Myeloma Research Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"<b>S.Z., O.P, R.G., D.D. G.K, M.H, P.F, C.W.A.L-C.<\/b>: no relevant disclosures. <b>S.S.<\/b>: Consulting or advisory role for Janssen, Bristol-Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, Abbvie and Regeneron; Research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis and Bristol-Myers Squibb; <b>L.S.<\/b>: Consulting or Advisory role for Janssen Oncology; <b>O.C.P.<\/b>: Consulting or Advisory role for BMS\/Celgene\/Juno, Legend Biotech; <b>A.A.<\/b>: Consulting or Advisory role for BMS, Karyopharm, Research funding from Abbvie, Adaptive biotechnologies; <b>J.A.D.<\/b>: consultancy for Janssen; <b>H.H<\/b>.; Consulting or Advisory role for Sanofi, BMS\/Celgene, Janssen; speaker\u2019s bureau: Janssen, Karyopharm, Amgen; <b>D.S<\/b>.: Consulting or Advisory role for Sanofi, GSK, BMS\/Celgene, Janssen, Abbvie, Pfizer, Arcellx, BiolineRx, Astrazeneca, research funding from Pfizer; <b>L.D.A. Jr<\/b>: consulting or advisory board role for Janssen, Celgene, Bristol Myers Squibb, Amgen, GlaxoSmithKline, AbbVie, BeiGene, Cellectar, Sanofi, Karyopharm, Oncopeptides, and Prothena. <b>J.M<\/b>: Honoraria: Kite, a Gilead company, AlloVir, Magenta Therapeutics, Nektar, Sana Biotechnology; Consulting or Advisory Role: Kite, a Gilead company, Juno Therapeutics, AlloVir, Magenta Therapeutics, EcoR1 Capital, CRISPR therapeutics; Speakers\u2019 Bureau: Kite\/Gilead; Research Funding: Novartis (Inst), Fresenius Biotech (Inst), Astellas Pharma (Inst), Bellicum Pharmaceuticals (Inst), Novartis (Inst), Gamida Cell (Inst), Pluristem Therapeutics (Inst), Kite, a Gilead company (Inst), AlloVir (Inst); Travel, Accommodations, Expenses: Kite, a Gilead company; <b>A.R.<\/b>: consultant for Sanofi, BMS, Janssen, and Adaptive. C.R. is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva; <b>C.L.F<\/b>: honoraria and consulting- Bristol Myers Squibb, Seattle Genetics, Celgene, AbbVie, Sanofi, Incyte, Amgen, ONK Therapeutics & Janssen; and research funding from Bristol Myers Squibb, Janssen, and Roche\/Genentech; <b>F.L.L.<\/b>: Scientific Advisory Role\/Consulting Fees: A2, Allogene, Amgen, Bluebird Bio, BMS, Calibr, Caribou, Cowen, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Umoja, Pfizer; Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), 2SeventyBio (Institutional), BMS (Institutional), National Cancer Institute (R01CA244328 MPI: Locke; P30CA076292 PI: Cleveland), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke); Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or Editorial Activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer <b>S.R.<\/b>: Honoraria: BMs, Jansssen; Consulting or Advisory Role: Genentech; Research Funding: Janssen, C4 therapeutics, Gracell, Heidelberg Pharma; <b>J.K.<\/b>: Consulting or Advisory Role: Janssen Oncology; Honoraria: GPCR therapeutics; <b>Y.L.<\/b>: Consulting or Advisory role: Kite\/Gilead, BMS, Vineti, Janssen Oncology, Pfizer; Sanofi, NexImmune, Caribou biosciences, Regeneron, Genentech, Fosun Kite, Chimeric Therapeutics, Adicet Bio, Nektar; Research Funding: Janssen Oncoloyg, BMS, Merck, Takeda, Boston Scientific, Kite\/Gilead, Bluebird Bio; <b>K.K.P.<\/b>: Consulting or Advisory Role: Celgene, BMS, Janssen, Pfizer, Arcellx, Karyopharm Therapeutics, Merck, Cellectis, Caribou Biosciences, Takeda, Abbvie, Travel, Accomodation, Expenses: BMS; Research funding: Celgene\/BMs, Takeda, Janssen, Cellectis, Nektar, Abbvie\/Genentech, Precision Biosciences, Allogene Therapeutics; <b>S.K.<\/b>: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech\/Rocher, Abbvie, BMS\/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accomodation and expenses: Abbvie, pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS\/Celgene; <b>D.K.H.<\/b>: Research funding from Bristol-Myers Squibb, Karyopharm, and Adaptive Biotech; Consulting or advisory role for Bristol-Myers Squibb, Janssen, Pfizer, and Karyopharm. D.K.H is also supported by the Pentecost Family Myeloma Research Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"42"}}